Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01171482
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Chung-Ang University
- Target Recruit Count
- 63
- Registration Number
- NCT01170104
- Locations
- 🇰🇷
Chung-Ang University Hospital, Dongjak, Seoul, Korea, Republic of
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 13
- Registration Number
- NCT01159327
- Locations
- 🇰🇷
National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
- Conditions
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Loma Linda University
- Target Recruit Count
- 8
- Registration Number
- NCT01141478
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
Sorafenib Plus S-1 in Advanced Solid Tumors
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 30
- Registration Number
- NCT01128998
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan City, Taiwan
Sorafenib for Imatinib/Sunitinib-failed GIST
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 39
- Registration Number
- NCT01091207
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT01078961
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 277
- Registration Number
- NCT01076010
- Locations
- 🇨🇱
Site 122, Santiago, Chile
🇷🇴Site 441, Bucharest, Romania
🇺🇦Site 496, Donetsk, Ukraine
Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- JSehouli
- Target Recruit Count
- 174
- Registration Number
- NCT01047891
- Locations
- 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany
A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT01041482
- Locations
- 🇨🇳
Jianhui Ma, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.